Longitudinal lipid profile variations and clinical change in Alzheimer's disease dementia

Página do item simplificado
dc.citation.volume646
dc.contributor.authorde Oliveira, Fabricio Ferreira [UNIFESP]
dc.contributor.authorChen, Elizabeth Suchi [UNIFESP]
dc.contributor.authorSmith, Marilia Cardoso [UNIFESP]
dc.contributor.authorFerreira Bertolucci, Paulo Henrique [UNIFESP]
dc.coverageClare
dc.date.accessioned2020-07-17T14:02:16Z
dc.date.available2020-07-17T14:02:16Z
dc.date.issued2017
dc.description.abstractHypercholesterolemia and statin use have been unevenly associated with clinical change in Alzheimer's disease dementia. In this longitudinal study, 192 consecutive outpatients with late-onset Alzheimer's disease dementia were stratified according to APOE haplotypes, and followed for one year to investigate associations of lipid profile variations and lipophilic statin therapy with changes in cognition, caregiver burden, basic and instrumental functionality. Overall, 102 patients (53.1%) carried APOE4+ haplotypes and 90 (46.9%) carried APOE4- haplotypesen
dc.description.abstract189 patients (98.4%) used either a cholinesterase inhibitor, or Memantine, or bothen
dc.description.abstract144 patients had dyslipidemias and 143 of them received statin therapy. Total cholesterol, LDL-cholesterol, Mini-Mental State Examination scores, and functional independence scores were significantly lower at the end of the follow-up, while Clinical Dementia Rating sum-of-boxes scores were higher. Exclusively for APOE4- carriers, rising LDL-cholesterol levels were associated with a trend toward improvements in the Index of Independence in Activities of Daily Living (beta=0.010en
dc.description.abstractrho= 0.16), whereas rising HDL-cholesterol levels were associated with lowered scores (beta = -0.051en
dc.description.abstractrho= 0.04). Lipophilic statin therapy had non-significant protective effects over Clinical Dementia Rating sum-of boxes score variations only for APOE4- carriers. APOE4- haplotypes might enhance lipid availability to protect neuronal membranes, thus overcoming their supposed dysfunction in cholesterol metabolism, while APOE4+ carriers have inefficient neural repair mechanisms. In conclusion, APOE haplotypes seem to influence the protective effects of lipid profile variations for patients with Alzheimer's disease dementia, but current evidence is insufficient to propose lipid-lowering drugs as specific anti-dementia therapy. (C) 2017 Elsevier B.V. All rights reserved.en
dc.description.affiliationFed Univ Sao Paulo UNIFESP, Escola Paulista Med, Dept Neurol & Neurosurg, Rua Botucatu 740, BR-04023900 Sao Paulo, SP, Brazil
dc.description.affiliationFed Univ Sao Paulo UNIFESP, Escola Paulista Med, Dept Morphol & Genet, Sao Paulo, SP, Brazil
dc.description.affiliationUnifespFed Univ Sao Paulo UNIFESP, Escola Paulista Med, Dept Neurol & Neurosurg, Rua Botucatu 740, BR-04023900 Sao Paulo, SP, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipCAPES - Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
dc.description.sponsorshipFAPESP - The State of Sao Paulo Research Foundation
dc.description.sponsorshipIDCAPES: 1067/10
dc.description.sponsorshipIDFAPESP: 2015/10109-5
dc.format.extent36-42
dc.identifierhttp://dx.doi.org/10.1016/j.neulet.2017.03.003
dc.identifier.citationNeuroscience Letters. Clare, v. 646, p. 36-42, 2017.
dc.identifier.doi10.1016/j.neulet.2017.03.003
dc.identifier.issn0304-3940
dc.identifier.urihttps://repositorio.unifesp.br/handle/11600/54718
dc.identifier.wosWOS:000401679600007
dc.language.isoeng
dc.publisherElsevier Ireland Ltd
dc.relation.ispartofNeuroscience Letters
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectAlzheimer Diseaseen
dc.subjectDementiaen
dc.subjectNeuropsychiatryen
dc.subjectDrug therapyen
dc.subjectCholesterolen
dc.subjectHydroxymethylglutaryl-CoA Reductaseen
dc.subjectInhibitorsen
dc.titleLongitudinal lipid profile variations and clinical change in Alzheimer's disease dementiaen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Artigos